EUVIMEDScopri EUVIMED
Übersichtsarbeit

The cytoplasmic sensor, the AIM2 inflammasome: A precise therapeutic target in vascular and metabolic diseases

Jiuguo Lin, Jiaojiao Wang, Jian Fang, Meihang Li, Suowen Xu, Peter J Little, Dongmei Zhang iD, Zhiping Liu iD

British Journal of Pharmacology · 2024-06 · 181 (12) · 1695-1719

DOI: 10.1111/bph.16355 ↗

At a glance

Übersichtsarbeit in British Journal of Pharmacology, published online on 2024-03-25. Written by Jiuguo Lin and 7 co-authors. Institution: State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, China. Major MEDLINE topics: Inflammasomes, DNA-Binding Proteins, Metabolic Diseases. Cited 21 times so far (Crossref); 192 references. Funded by: Traditional Chinese Medicine Bureau of Guangdong Province Research Project, National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Cardio‐cerebrovascular diseases encompass pathological changes in the heart, brain and vascular system, which pose a great threat to health and well‐being worldwide. Moreover, metabolic diseases contribute to and exacerbate the impact of vascular diseases. Inflammation is a complex process that protects against noxious stimuli but is also dysregulated in numerous so‐called inflammatory diseases, one of which is atherosclerosis. Inflammation involves multiple organ systems and a complex cascade of molecular and cellular events. Numerous studies have shown that inflammation plays a vital role in cardio‐cerebrovascular diseases and metabolic diseases. The absent in melanoma 2 (AIM2) inflammasome detects and is subsequently activated by double‐stranded DNA in damaged cells and pathogens. With the assistance of the mature effector molecule caspase‐1, the AIM2 inflammasome performs crucial biological functions that underpin its involvement in cardio‐cerebrovascular diseases and related metabolic diseases: The production of interleukin‐1 beta ( IL-1β ), interleukin‐18 ( IL-18 ) and N‐terminal pore‐forming Gasdermin D fragment (GSDMD‐N) mediates a series of inflammatory responses and programmed cell death (pyroptosis and PANoptosis). Currently, several agents have been reported to inhibit the activity of the AIM2 inflammasome and have the potential to be evaluated for use in clinical settings. In this review, we systemically elucidate the assembly, biological functions, regulation and mechanisms of the AIM2 inflammasome in cardio‐cerebrovascular diseases and related metabolic diseases and outline the inhibitory agents of the AIM2 inflammasome as potential therapeutic drugs.

Subjects

MeSH terms (MEDLINE)

InflammasomesDNA-Binding ProteinsMetabolic DiseasesHumansAnimalsVascular DiseasesInflammation

Author keywords

AIM2PANoptosisinflammasomemetabolic diseasespyroptosisvascular diseases

Substances

InflammasomesAIM2 protein, humanDNA-Binding Proteins

Authors and institutions

  • State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, China.
  • Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou, China.
  • International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, Jinan University, Guangzhou, China.
  • Huadu District People's Hospital of Guangzhou, Guangzhou, China.
  • Institute of Endocrine and Metabolic Diseases, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • Pharmacy Australia Centre of Excellence, School of Pharmacy, University of Queensland, Woolloongabba, Queensland, Australia.

ORCID profiles: Dongmei Zhang, Zhiping Liu

Funding

  • Traditional Chinese Medicine Bureau of Guangdong Province Research Project
  • National Natural Science Foundation of China
  • Guangdong Basic and Applied Basic Research Foundation
  • Basic and Applied Basic Research Foundation of Guangdong Province

Cite

APA

Lin, J., Wang, J., Fang, J., Li, M., Xu, S., Little, P. J., Zhang, D., & Liu, Z. (2024). The cytoplasmic sensor, the AIM2 inflammasome: A precise therapeutic target in vascular and metabolic diseases. British Journal of Pharmacology, 181(12), 1695-1719. https://doi.org/10.1111/bph.16355

Vancouver

Lin J, Wang J, Fang J, Li M, Xu S, Little PJ, et al. The cytoplasmic sensor, the AIM2 inflammasome: A precise therapeutic target in vascular and metabolic diseases. British Journal of Pharmacology. 2024;181(12):1695-1719. doi:10.1111/bph.16355

BibTeX
@article{Lin2024,
  author = {Lin, Jiuguo and Wang, Jiaojiao and Fang, Jian and Li, Meihang and Xu, Suowen and Little, Peter J and Zhang, Dongmei and Liu, Zhiping},
  title = {The cytoplasmic sensor, the AIM2 inflammasome: A precise therapeutic target in vascular and metabolic diseases},
  journal = {British Journal of Pharmacology},
  year = {2024},
  volume = {181},
  number = {12},
  pages = {1695--1719},
  doi = {10.1111/bph.16355}
}
Start for free →